Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Van Rhee, Frits  [Clear All Filters]
Journal Article
Sun F, Cheng Y, Wanchai V, Guo W, Méry D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, et al. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15(1):615.
Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013;8(9):e74191.
Mohan M, Kendrick S, Szabo A, Yarlagadda NK, Atwal D, Pandey Y, Roy AMariam, Parikh R, Lopez J, Thanendrarajan S, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2021.
Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, Van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, et al. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2018.
Garg TK, Garg S, Miousse IR, Wise SY, Carpenter AD, Fatanmi OO, Van Rhee F, Singh VK, Hauer-Jensen M. Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation. Radiat Res. 2023.
Rafae A, Van Rhee F, Hadidi SAl. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2023.
Liu Y-C, Szmania S, Van Rhee F. Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat Cancer. 2014;2014(4):15-27.
Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, Van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hajek R, Cook G, et al. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2022.